Revista de cardiología general e intervencionista

Colchicine for Prevention of in Stent Restenosis in Patients with Bare Metal Stents (Colisr-BMS Trial)

Abstract

Mohammed Habib

Background: In stent restenosis has been a considerable major problem with bare-metal stents (BMS). Pharmacological interventions to decrease Instent restenosis (ISR) could be of clinical relevance. Colchicine is associated with reduced inflammation and can be a reduced ISR rate when administered to patients after BMS implantation. The current study aimed to evaluate the efficacy of colchicine additional to BMS in the prevention of BMS restenosis in patients who underwent percutaneous coronary intervention (PCI).

Methods: The current clinical study was conducted at Gaza city. It involved 90 patients who were scheduled for coronary angioplasty procedure. The patients were divided into three groups: The first group, underwent BMS implantation and received colchicine 0.5 mg twice daily for six months. The second group, underwent BMS implantation alone. The third group, underwent DES implantation. All the patients were followed up for six months. The primary endpoint was clinical ISR at 6months. Secondary endpoints included target vessel revascularization (TVR) and stent thrombosis (ST).

Results: The mean age of the patients was 60.03 ± 7.8 years. After 6 months follow-up, significant differences were found in clinical ISR rate among the three groups (3% for the colchicine group, 23% for BMS alone and 0% for DES group, P=0.005). In addition, There were significant differences in TVR rate (3% for the colchicine group, 27% for BMS alone and 0% for DES group, P=0.002). However, there were no significant differences in the rate of stent thrombosis (0% for the colchicine group, 3% for BMS alone and 0% for DES group, P= 1).

Conclusion: Colchicine is associated with reduced ISR and TVR rate when administered to patients who underwent PCI with BMS as compared to BMS alone.